Azilsartan Tablets Special Drug Use Surveillance: Long-term Use
Launched by TAKEDA · Mar 17, 2014
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
This surveillance was designed to evaluate the safety and efficacy of long-term use of azilsartan tablets (Azilva Tablets) in hypertensive patients in daily medical practice.
The usual dosage for adult is 20 mg of azilsartan administered orally once daily. The dose can be adjusted according to the patient's age and condition. The maximum daily dose is 40 mg.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hypertensive patients
- Exclusion Criteria:
- • 1. Patients with a history of hypersensitivity to any of the ingredients of Azilsartan
- • 2. Patients who are pregnant or having possibilities of being pregnant
About Takeda
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Osaka, , Japan
Patients applied
Trial Officials
Study Director
Study Director
Takeda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials